Proven Panel
This page updates as FDA acts. Follow the 503A track to get the decision in your inbox. Follow the 503A track
How peptides are regulated

Peptide status map

Where each peptide actually sits

Every compound in the library, placed in one of the four regulatory worlds. Filter by stage, then open the entry for the sourced detail. Placement describes status, not a recommendation.

Filter by stage

FDA-approved drug

Recognized 2 compounds

Reviewed and approved by the FDA for a specific use. Legal, proven for that use, prescribed and pharmacy-dispensed.

Semaglutide
FDA-approved (Ozempic/Wegovy); bulk compounding excluded
Open entry
Elamipretide (SS-31) SS-31 ⚑ Provisional
FDA accelerated approval (Barth syndrome, Sept 2025); confirmatory trial pending; other mito indications investigational
Open entry

Compounding pathway

Case-by-case 2 compounds

In the 503A compounding process — nominated, in Category 1 or 2, or awaiting an FDA decision. Legal to compound is not the same as approved.

BPC-157
Under PCAC review (Jul 23, 2026); not yet on the 503A list
WADA-flagged Open entry
Thymosin Beta-4 TB-500
Under PCAC review (Jul 23, 2026); not yet on the 503A list
WADA-flagged Open entry

Gray-market "research chemical"

Caution 15 compounds

Sold "not for human use," outside FDA oversight of identity, purity, or dose. Where a peptide sits when it fits no other world — often permanently.

Copper Tripeptide-1 GHK-Cu ⚑ Provisional
Category 2 withdrawn (injectable); reported ~Feb 2027 review
Open entry
Thymosin Alpha-1 Tα1
Category 2 withdrawn; approved abroad (Zadaxin), not in the US
Open entry
CJC-1295
Category 2 nomination withdrawn; no active review
WADA-flagged Open entry
Ipamorelin
Category 2 (dual-listed); no active review
WADA-flagged Open entry
Melanotan II MT-II ⚑ Provisional
Illegal to sell; reported ~Feb 2027 review
Open entry
KPV ⚑ Provisional
Preclinical; no human trials; scheduled for July 2026 PCAC 503A review
Open entry
MOTS-c ⚑ Provisional
Preclinical; early registered human trial
Open entry
AOD-9604 ⚑ Provisional
Obesity development discontinued (2007); not FDA-approved; gray-market/compounded
Open entry
Follistatin 344 FS-344 ⚑ Provisional
Preclinical/early gene-therapy research; no approved product
Open entry
IGF-1 LR3 ⚑ Provisional
Research reagent; no approved human-therapeutic pathway
WADA-flagged Open entry
LL-37 ⚑ Provisional
Mostly preclinical; LL-37 and derivatives in/pre Phase II
Open entry
DSIP ⚑ Provisional
No approved product; preclinical/early research only
Open entry
Kisspeptin-10 ⚑ Provisional
Investigational; early-phase academic trials
Open entry
VIP (Vasoactive Intestinal Peptide) VIP ⚑ Provisional
Analogue (aviptadil) failed pivotal COVID-19 trial; no approved product
Open entry
Glutathione (injectable) GSH ⚑ Provisional
marketed gray-market/compounded; no US approval for cosmetic or wellness use
Open entry

Sold as a supplement

Limited 1 compound

Marketed on supplement shelves, though most peptides do not legally qualify as dietary ingredients.

NAD+
Legal supplement (NMN/NR); IV NAD+ not FDA-approved
Open entry
Read carefully

A peptide sitting in the gray-market row isn’t “on its way” to approval — most will stay there. Being on this map doesn’t make anything legal to use, and dates marked provisional are trade reporting we haven’t confirmed against a primary FDA notice yet. Check each entry’s sources for the current status.